Coronary Heart DiseasePhase 2NCT06097663

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

A Phase 2 study testing MAS825 and DFV890 in people with Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP), run by Novartis Pharmaceuticals at 6 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)
What is being tested?: MAS825 and DFV890
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 31 participants
Where: 6 sitesin 3 countries
Study dates: 15 Feb 2024to 4 Nov 2024
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Male and female participants aged between 18 - 80 years (inclusive) at the start of screening will be included.
Participants must have a body mass index (BMI) within the range of 18 - 40 kg/m2 at screening. BMI = Body weight (kg) / [Height (m)]2.
Documented spontaneous myocardial infarction (MI) (diagnosed according to the universal MI criteria with or without evidence of ST segment elevation) at least 30 days before the start of screening (Thygesen et al 2007).
Known presence of CHIP, restricted to driver mutations in TET2 or DNMT3A with a VAF ≥2%, as documented in the participant's medical history.
For participants on statin therapy (HMG-CoA reductase inhibitor) as clinically indicated, participants must be on a stable regimen (at least 4 weeks before randomization), with no planned statin dose changes over the course of the trial treatment period. Unplanned statin dose changes during the trial treatment period may occur.

Who cannot join

Patients receiving concomitant medications that are known to be strong or moderate inducers of cytochrome CYP2C9 enzyme and/or strong inducers of CYP3A, strong inhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatment cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study.
At screening, pre-malignant clonal cytopenias or clonal cytopenia of unknown significance (CCUS).
History of ongoing, chronic, or major recurrent infectious disease, at the discretion of the Investigator, at the start of screening.
Patients with suspected or proven immunocompromised state at screening.
Use of any biologic drugs targeting the immune system within 26 weeks of Day 1.
Multi-vessel coronary artery bypass graft (CABG) surgery within the past 3 years prior to the start of screening.
Planned coronary revascularization (percutaneous coronary intervention (PCI) or CABG) or any other major surgical procedure during the study (until End of Study (EOS)).
Symptomatic Class IV heart failure (New York Heart Association [NYHA]) at the start of screening.

Trial locations and contacts

6 sites in 3 countries.

Country

City, postcode or hospital

6 sites in 3 countries

Germany3 sites

Novartis Investigative Site
Bonn, 53105
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590
Novartis Investigative Site
München, 80636

Other trials in Germany

United States2 sites

Vanderbilt University Medical Cent
Nashville, Tennessee, 37232-8805
Washington University
St Louis, Missouri, 63110

Other trials in United States

Canada1 site

Novartis Investigative Site
Montreal, Quebec, H1T 1C8

Other trials in Canada

About this study

Official title: A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in an Adult Population With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency [VAF] ≥2%).

Read the detailed description

This was a multi-center, randomized, placebo-controlled, participant- and investigator-blinded study.

The study consisted of a screening period up to 30 days; a treatment period of approximately 12 weeks with an end of treatment (EOT) visit on Day 85, which is one day after the last dose of DFV890 or placebo; a follow-up period of approximately 1 week; and a standard safety follow-up call approximately 30 days following the last dose. The overall study duration is approximately 21 weeks.

Participants were randomized to one of five treatment sequences. Based on the treatment sequence assignments, participants started on either a combination of MAS825 and placebo, DFV890 and placebo, or placebo and placebo on Day 1, and then, within each DFV890 treatment sequence, participants received up-titrating doses of DFV890 or placebo at the corresponding study visits. None of the treatment sequences included a combination of both active DFV890 and active MAS825.

Conditions: Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Being tested: MAS825, MAS825 Placebo, DFV890, DFV890 placebo
Keywords: coronary heart disease, CHIP, inflammatory marker reduction, NLRP3 inflammasome inhibitor
Medical subject headings: Coronary Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

MAS825Drug
Active MAS825 single dose
MAS825 PlaceboDrug
MAS825 placebo single dose
DFV890Drug
Oral tablet of DFV890 active once daily
DFV890 placeboDrug
Oral tablet of DFV890 placebo once daily

Study groups in NCT06097663
Study group	Role	What they receive
Treatment Sequence 1	Experimental	On Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84. Receives: Drug: MAS825; Drug: DFV890 placebo
Treatment Sequence 2	Experimental	On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64. Receives: Drug: MAS825 Placebo; Drug: DFV890; Drug: DFV890 placebo
Treatment Sequence 3	Experimental	On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64. Receives: Drug: MAS825 Placebo; Drug: DFV890; Drug: DFV890 placebo
Treatment Sequence 4	Experimental	On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg. Receives: Drug: MAS825 Placebo; Drug: DFV890
Treatment Sequence 5	Placebo comparator	On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84. Receives: Drug: MAS825 Placebo; Drug: DFV890 placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor.
The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.
Measured: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model
Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor.
The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.
Measured: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model
Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor.
Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.
Measured: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.

Secondary outcomes (2)

Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state
Ctrough is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.
Measured: After the last dose of each 3-week dosing period: Day 22 pre-dose, Day 43 pre-dose, Day 64 pre-dose, or Day 85, depending on treatment sequence assignment
MAS825 Serum Concentrations
MAS825 serum concentrations were determined using a validated target-based sandwich ELISA.
Measured: Day 22, Day 43, Day 64 and Day 85

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 Feb 20244 Nov 2024

First posted24 Oct 2023
Study start15 Feb 2024
Primary completion27 Oct 2024
Study completion4 Nov 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (2)Papers the sponsor has linked to this study.
Other trials for Coronary Heart DiseaseStudies of the same condition, open and under way.
More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 31 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06097663
Sponsor's protocol ID: CADPT15A12201
Other IDs: 2023-506741-34-00, 2023
Status last verified: Mar 2026
First submitted: 18 Oct 2023
Last updated: 9 Apr 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Publications

Sumida K, Obeng EA, Kovesdy CP. Clonal Hematopoiesis in Kidney Disease. Clin J Am Soc Nephrol. 2026 Apr 1;21(4):719-721. doi: 10.2215/CJN.0000000895. Epub 2025 Sep 11. No abstract available.
PubMed 40932796
Avolio E, Bassani B, Campanile M, Mohammed KA, Muti P, Bruno A, Spinetti G, Madeddu P. Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing? Pharmacol Rev. 2025 Mar;77(2):100033. doi: 10.1016/j.pharmr.2024.100033. Epub 2024 Dec 24.
PubMed 40148035

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases

All Coronary Heart Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in an Adult Population With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
ClinicalTrials.gov ID: NCT06097663
Acronym / sponsor ID: CADPT15A12201
Conditions: Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Keywords: coronary heart disease, CHIP, inflammatory marker reduction, NLRP3 inflammasome inhibitor
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 31 participants (actual)
Lead sponsor: Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
Study start: 15 Feb 2024 (actual)
Primary completion: 27 Oct 2024 (actual)
Study completion: 4 Nov 2024 (actual)
First posted: 24 Oct 2023 (actual)
Results: Posted 27 Mar 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This was a multi-center, randomized, placebo-controlled, participant- and investigator-blinded study.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 5

Arm	Type	Receives
Treatment Sequence 1	Experimental	Drug: MAS825, Drug: DFV890 placeboOn Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
Treatment Sequence 2	Experimental	Drug: MAS825 Placebo, Drug: DFV890, Drug: DFV890 placeboOn Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64.
Treatment Sequence 3	Experimental	Drug: MAS825 Placebo, Drug: DFV890, Drug: DFV890 placeboOn Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64.
Treatment Sequence 4	Experimental	Drug: MAS825 Placebo, Drug: DFV890On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg.
Treatment Sequence 5	Placebo comparator	Drug: MAS825 Placebo, Drug: DFV890 placeboOn Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Male and female participants aged between 18 - 80 years (inclusive) at the start of screening will be included.
Participants must have a body mass index (BMI) within the range of 18 - 40 kg/m2 at screening. BMI = Body weight (kg) / [Height (m)]2.
Documented spontaneous myocardial infarction (MI) (diagnosed according to the universal MI criteria with or without evidence of ST segment elevation) at least 30 days before the start of screening (Thygesen et al 2007).
Known presence of CHIP, restricted to driver mutations in TET2 or DNMT3A with a VAF ≥2%, as documented in the participant's medical history.
For participants on statin therapy (HMG-CoA reductase inhibitor) as clinically indicated, participants must be on a stable regimen (at least 4 weeks before randomization), with no planned statin dose changes over the course of the trial treatment period. Unplanned statin dose changes during the trial treatment period may occur.

Key exclusion criteria (8 listed)

Patients receiving concomitant medications that are known to be strong or moderate inducers of cytochrome CYP2C9 enzyme and/or strong inducers of CYP3A, strong inhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatment cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study.
At screening, pre-malignant clonal cytopenias or clonal cytopenia of unknown significance (CCUS).
History of ongoing, chronic, or major recurrent infectious disease, at the discretion of the Investigator, at the start of screening.
Patients with suspected or proven immunocompromised state at screening.
Use of any biologic drugs targeting the immune system within 26 weeks of Day 1.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
MAS825Active MAS825 single dose	Drug	Treatment Sequence 1
MAS825 PlaceboMAS825 placebo single dose	Drug	Treatment Sequence 2, Treatment Sequence 3, Treatment Sequence 4, Treatment Sequence 5
DFV890Oral tablet of DFV890 active once daily	Drug	Treatment Sequence 2, Treatment Sequence 3, Treatment Sequence 4
DFV890 placeboOral tablet of DFV890 placebo once daily	Drug	Treatment Sequence 1, Treatment Sequence 2, Treatment Sequence 3, Treatment Sequence 5

Primary outcome

Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.
Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model
Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.
Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model
Time frame: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.
Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.

2 secondary outcomes

Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state
Time frame: After the last dose of each 3-week dosing period: Day 22 pre-dose, Day 43 pre-dose, Day 64 pre-dose, or Day 85, depending on treatment sequence assignment
MAS825 Serum Concentrations
Time frame: Day 22, Day 43, Day 64 and Day 85

Results and safety

Results posted to the registry on 27 Mar 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Treatment Sequence 1	11	11
Treatment Sequence 2	8	7
Treatment Sequence 3	8	5
Treatment Sequence 4	2	2
Treatment Sequence 5	2	1

Primary outcome: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model

Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment). Geometric mean (80% Confidence Interval). Unit: ratio serum levels of IL-6

Measure	DFV890 10 mg n = 9	DFV890 25 mg n = 15	DFV890 50 mg n = 9	DFV890 100 mg n = 14	Placebo n = 17
Value	0.8602 (0.7117 to 1.0397)	0.7558 (0.6615 to 0.8637)	0.7002 (0.6146 to 0.7976)	0.6657 (0.5495 to 0.8064)	1.1219 (0.9594 to 1.3120)

DFV890 10 mg vs Placebo: Ratio of the Geometric Mean: 0.7667 (80% CI 0.6012 to 0.9778), p = 0.0817, Emax model
DFV890 25 mg vs Placebo: Ratio of the Geometric Mean: 0.6737 (80% CI 0.5528 to 0.8210), p = 0.008, Emax model
DFV890 50 mg vs Placebo: Ratio of the Geometric Mean: 0.6241 (80% CI 0.5257 to 0.7409), p = 0.0009, Emax model

Population analysed: Participants in the pharmacodynamic (PD) analysis set with available data for the outcome measure. In this analysis, MAS825 data are excluded from the analysis (including placebo sessions following a MAS825 dose), in alignment with the primary objectives of the protocol and the corresponding statistical analysis plan.

Primary outcome: Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model

Measure	DFV890 10 mg n = 9	DFV890 25 mg n = 15	DFV890 50 mg n = 9	DFV890 100 mg n = 14	Placebo n = 17
Value	0.9088 (0.8825 to 0.9358)	0.9087 (0.8825 to 0.9357)	0.9087 (0.8825 to 0.9357)	0.9087 (0.8825 to 0.9357)	0.9767 (0.9427 to 1.0119)

DFV890 10 mg vs Placebo: Ratio of the Geometric Mean: 0.9305 (80% CI 0.8982 to 0.9638), p = 0.007, Emax model
DFV890 25 mg vs Placebo: Ratio of the Geometric Mean: 0.9304 (80% CI 0.8982 to 0.9638), p = 0.007, Emax model
DFV890 50 mg vs Placebo: Ratio of the Geometric Mean: 0.9304 (80% CI 0.8982 to 0.9638), p = 0.007, Emax model

Primary outcome: Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model

Time frame: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.. Geometric mean (80% Confidence Interval). Unit: ratio serum levels if IL-6

Measure	MAS825 n = 11	Placebo n = 17
Value	0.5406 (0.4287 to 0.6818)	1.1335 (0.9488 to 1.3541)

MAS825 vs Placebo: Ratio of the Geometric Mean: 0.4770 (80% CI 0.3561 to 0.6388), p = 0.0008, Regression, Linear

Population analysed: Participants in the pharmacodynamic (PD) analysis set with available data for the outcome measure. In this analysis, measurements of IL-6 on MAS825 data are managed considering the effect after 3 weeks from dosing.

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
DFV890 10 mg	0 of 10 (0%)	1 of 10 (10%)	0 of 10
DFV890 25 mg	0 of 16 (0%)	6 of 16 (37.5%)	0 of 16
DFV890 50 mg	0 of 9 (0%)	2 of 9 (22.2%)	0 of 9
DFV890 100 mg	0 of 16 (0%)	3 of 16 (18.8%)	0 of 16
MAS825	0 of 11 (0%)	7 of 11 (63.6%)	0 of 11
Placebo Sessions	0 of 22 (0%)	9 of 22 (40.9%)	0 of 22
Placebo Participants	0 of 18 (0%)	8 of 18 (44.4%)	0 of 18
DFV890 100 mg Follow-up	0 of 16 (0%)	3 of 16 (18.8%)	0 of 16
MAS825 Follow-up	0 of 11 (0%)	1 of 11 (9.1%)	0 of 11
Placebo Follow-up	0 of 2 (0%)	0 of 2 (0%)	0 of 2

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 40932796Sumida K, Obeng EA, Kovesdy CP. Clonal Hematopoiesis in Kidney Disease. Clin J Am Soc Nephrol. 2026 Apr 1;21(4):719-721. doi: 10.2215/CJN.0000000895. Epub 2025 Sep 11. No abstract available.
Derived from this study: PubMed 40148035Avolio E, Bassani B, Campanile M, Mohammed KA, Muti P, Bruno A, Spinetti G, Madeddu P. Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing? Pharmacol Rev. 2025 Mar;77(2):100033. doi: 10.1016/j.pharmr.2024.100033. Epub 2024 Dec 24.
A Plain Language Trial Summary is available on www.novctrd.comLink provided by the sponsor.
Individual participant dataSharing planned: Yes. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Related trials for Coronary Heart Disease

Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Novartis Pharmaceuticals study director

Novartis Pharmaceuticals

6 sites in 3 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing MAS825 and DFV890 in people with Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP), run by Novartis Pharmaceuticals at 6 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in Germany, United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model (time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06097663, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026; AzTrials last refreshed its copy on 6 Nov 2026.